UX111 (Ultragenyx Pharmaceutical Inc.) is an investigational single-infusion gene therapy proposed for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA).
UX111 (Ultragenyx Pharmaceutical Inc.) is an investigational single-infusion gene therapy proposed for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA).